Show simple item record

dc.contributor.authorNicholson, Joshua Men_US
dc.date.accessioned2014-01-30T16:13:40Z
dc.date.available2014-01-30T16:13:40Z
dc.date.issued2013-12-13
dc.identifier.citationMolecular Cytogenetics. 2013 Dec 13;6(1):57en_US
dc.identifier.urihttp://hdl.handle.net/10919/25227
dc.description.abstractThe promise to understand cancer and develop efficacious therapies by sequencing thousands of cancers has not occurred. Mutations in specific genes termed oncogenes and tumor suppressor genes are extremely heterogeneous amongst the same type of cancer as well as between cancers. They provide little selective advantage to the cancer and in functional tests have yet to be shown to be sufficient for transformation. Here I discuss the karyotyptic theory of cancer and ask if it is time for a new approach to understanding and ultimately treating cancer.en_US
dc.format.mimetypeapplication/pdfen_US
dc.language.isoen_US
dc.rightsCreative Commons Attribution 4.0 International*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.titleWill we cure cancer by sequencing thousands of genomes?en_US
dc.typeArticle - Refereeden_US
dc.date.updated2014-01-30T16:13:41Z
dc.description.versionPeer Reviewed
dc.rights.holderJoshua M Nicholson et al.; licensee BioMed Central Ltd.en_US
dc.title.serialMolecular Cytogenetics
dc.identifier.doihttps://doi.org/10.1186/1755-8166-6-57
dc.type.dcmitypeTexten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International
License: Creative Commons Attribution 4.0 International